System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 42463974 DOI: 10.1007/s00198-026-07981-z

Serum activin A and bone metabolism in patients undergoing hemodialysis.

Osteoporos Int 37(9):2465-2473

Authors: Yosuke Nakagawa, Hiroo Takahashi, Yuichiro Takahashi, Toru Hyodo, Miho Hida, Takao Suga, Takatoshi Kakuta, Yusuke Tomita, Michio Nakamura, Hirotaka Komaba

Affiliations

  • Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
  • Jinken Clinic, Ebina, Japan.
  • Medical Corporation Kuratakai, Hiratsuka, Japan.
  • Medical Corporation Showakai, Tokyo, Japan.
  • Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan. Medical Corporation Showakai, Tokyo, Japan.
  • Department of Transplant Surgery, Tokai University School of Medicine, Isehara, Japan.
  • Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan. The Institute of Medical Sciences, Tokai University, Isehara, Japan.

Abstract

UNLABELLED

Activin A, which promotes osteoclast differentiation, increases with declining kidney function, but its role in bone metabolism in kidney failure remains unclear. We found that higher activin A levels were associated with increased bone turnover markers, independent of parathyroid hormone levels.

PURPOSE

Activin A, produced by various cells including bone marrow stromal cells, immune cells, and osteoblasts, is thought to promote osteoclast differentiation. Serum activin A levels rise with declining kidney function, but its role in bone metabolism in kidney failure remains incompletely understood.

METHODS

Serum activin A levels were measured in 35 healthy individuals and 654 patients undergoing maintenance hemodialysis. Associations of serum activin A with tartrate-resistant acid phosphatase isoform 5b (TRACP5b), bone-specific alkaline phosphatase (BALP), and metacarpal bone mineral density were assessed using both unadjusted and multivariable-adjusted linear regression analyses. Serum activin A levels were also compared between patients with and without a history of fracture, and between those who developed incident fractures during follow-up and those who did not.

RESULTS

The median serum activin A level in hemodialysis patients was 733 pg/mL (interquartile range (IQR), 591-912), approximately 2.6-fold higher than that of healthy controls (277 pg/mL; IQR, 216-289; P < 0.001). Patients with higher activin A levels had longer dialysis durations, a higher prevalence of polycystic kidney disease, and higher serum phosphorus and alkaline phosphatase levels. Higher activin A levels were significantly associated with increased TRACP5b levels independently of intact parathyroid hormone levels, with a similar trend observed for BALP. Serum activin A levels were not associated with metacarpal bone mineral density, history of fracture, or incident fractures.

CONCLUSION

These findings suggest that in patients with kidney failure, elevated activin A may contribute to high bone turnover, although its ability to predict fracture risk appears limited. Further studies are warranted to investigate its potential as a therapeutic target.

MeSH

Parathyroid Hormone, Cells, Alkaline Phosphatase, Serum, Bone Remodeling, Kidney, Hormones, Phosphoric Monoester Hydrolases, Osteoporosis, History, Bone Density, Activins, Osteoclasts